 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
7 News |  |
- ||||| ARGX-111 / argenx
Clinical, Liquid biopsy: The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced #Cancer #Patients! Congrats @aftimosp @ChristianRolfo and team!! @OncoAlert @isliquidbiopsy (Twitter) - Jul 13, 2021
- || ARGX-111 / argenx
Clinical, Journal: The NHance Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. (Pubmed Central) - Jul 4, 2021
When escalated to 1 mg/kg, a partial response was reached. Furthermore, decreased numbers of CTC (75%) possibly by the enhanced tumor cell killing witnessed the modes of action of the drug, warranting further clinical investigation of ARGX-111.
- | ARGX-111 / argenx
Trial completion, Enrollment change, Metastases: A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. (clinicaltrials.gov) - Apr 21, 2017
P1b, N=24, Completed, Sponsor: arGEN-X BVBA
Furthermore, decreased numbers of CTC (75%) possibly by the enhanced tumor cell killing witnessed the modes of action of the drug, warranting further clinical investigation of ARGX-111. Recruiting --> Completed | N=35 --> 24
- ARGX-111 / argenx
Phase classification, Trial primary completion date, Metastases: A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. (clinicaltrials.gov) - Jul 29, 2016
P1b, N=35, Recruiting, Sponsor: arGEN-X BVBA
Recruiting --> Completed | N=35 --> 24 Phase classification: P1 --> P1b | Trial primary completion date: Dec 2015 --> Mar 2017
- ARGX-111 / argenx
New P1 trial, Metastases: A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. (clinicaltrials.gov) - Feb 2, 2014
P1, N=35, Recruiting, Sponsor: arGEN-X BVBA